Picture EBD Group BIO-Europe 2023 Munich BEU23 650x100px
Document › Details

BioIndustry Assocation (BIA). (1/25/17). "Press Release: Innovative UK Companies Tackle Antimicrobial Resistance, Dementia and Long Term Disease Thanks to Government £26 Million Start-up Funding Awards".

Region Region United Kingdom (GB)
Organisations Organisation BioIndustry Association (BIA) (GB)
  Organisation 2 Biomedical Catalyst (GB)
  Group United Kingdom (GB) (govt)
Products Product business development (state/region)
  Product 2 BIOTECH
Persons Person Javid, Sajid (United Kingdom (govt) 2016 Business Secretary NOT ANYMORE 2017)
  Person 2 Bates, Steve (BIA 201211 CEO)

BIA members among companies awarded Biomedical Catalyst 2016 funding

Innovative small British companies are tackling key healthcare challenges thanks to new government funding for start-up and scaling companies announced today.

Twelve BIA member companies were among those awarded funding through the Biomedical Catalyst 2016 scheme. Launched in July last year by former Business Secretary, Sajid Javid, the Biomedical Catalyst 2016 saw over £26 million of funding awarded across 66 projects by Innovate UK, the Medical Research Council and Scottish Enterprise.

Steve Bates, BIA CEO, commented: “UK life science company innovation is key to tackling key healthcare challenges we all face. I’m delighted to see so many of our members receive funding as part of this latest competition. The consistent campaigning of the BIA and our members has ensured that this key source of early-stage funding will continue to support the development of new life-changing medical treatments, diagnostics and devices, and underpin economic growth for the future.”

“The bioscience sector requires a sustained funding ladder where promising innovations and companies have the most optimal environment from start up to liquidity. The Biomedical Catalyst scheme has proved to be an integral rung on that ladder – crowding in additional private sector investment, allowing the UK to lead the way in tackling global health challenges such as dementia, type one diabetes and antimicrobial resistance.

“It’s pleasing to see for the first time the participation of Scottish Enterprise in this UK scheme for the first time – I believe there is opportunity for other devolved nations and regions to look on this as a model to develop investment in their own local SME healthcare ecosystems going forward.”

Previous recipients of Biomedical Catalyst funding, BIA member Discuva, were awarded funding for novel Gram negative antibiotic drug discovery.

David Williams, CEO Discuva, said: “We’re very grateful of being awarded another Innovate UK award, which is further endorsement of our totally new approach to the creation of much-needed Gram Negative antibiotics. Adding more candidates into our development pipeline will ultimately lead to more clinical weapons in our armoury for fighting anti-microbial resistance in our hospitals and communities.”

The long running Biomedical Catalyst scheme has seen post-award funded companies and academics realise in excess of a further billion pounds in the form of additional private finance, grant funding, via licencing or through acquisition.

The BIA has lead a highly successful campaign to keep the BMC going since 2009 – you can find out more by downloading our “BIA and the Biomedical Catalyst” infographic here.

The new Biomedical Catalyst 2017 Round 1 is now open for applications. More details are available from Innovate UK.

Notes to editors


Details of latest award winners, feasibility studies
Details of latest award winners, early stage awards
BIA and the Biomedical Catalyst
Biomedical Catalyst re-filled for four years

BioIndustry Association

Established over 25 years ago at the infancy of biotechnology, the BioIndustry Association (BIA) is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector. The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives.

For further information, please go to and


Jess Gray

Senior Communications Executive, BioIndustry Association


Phone: 020 7630 2197 

Record changed: 2023-06-05


Picture EBD Group BIO-Europe 2023 Munich BEU23 650x200px

More documents for BioIndustry Association (BIA) (GB)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group World of Partnering Opportunities 650x300px

» top